Navigation Links
Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
Date:12/9/2010

de 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death
  • Patients with isolated elevations of transaminase > 1.5 X ULN also had a higher rate of febrile neutropenia grade 4 but did not have an increased incidence of toxic death
  • Bilirubin, AST or ALT, and alkaline phosphatase values should be obtained prior to each cycle of Taxotere® therapy

  • Taxotere® therapy should not be given to patients with neutrophil counts of < 1500 cells/mm3
  • In order to monitor the occurrence of neutropenia, which may be severe and result in infection, frequent blood-cell counts should be performed on all patients receiving Taxotere®

  • Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients who received a 3-day dexamethasone premedication
  • Hypersensitivity reactions require immediate discontinuation of Taxotere® infusion and administration of appropriate therapy

  • Taxotere® must not be given to patients who have a history of severe hypersensitivity reactions to Taxotere® or to other drugs formulated with polysorbate 80

  • Severe fluid retention occurred in 6.5% (6/92) of patients despite use of a 3-day dexamethasone premedication regimen. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).

  • Neutropenia (<2,000 neutrophils/mm3) occurs in virtually all patients given 60-100 mg/m2 of Taxotere® and grade 4 neutropenia (<500 cells/mm3) occurs in 85% of patients given 100 mg/m2 and 75% of patients given 60 mg/m2

  • Patients should be premedicated with oral cortico
    '/>"/>

  • SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
    2. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
    3. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
    4. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
    5. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
    6. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
    7. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
    8. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    9. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
    10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
    11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... 2015   Mallinckrodt plc (NYSE: MNK ), ... 13, 2015, at the Bank of America Merrill Lynch 2015 ... Las Vegas, Nev. ... Officer, and Cole Lannum , Senior Vice President of ... in a session scheduled to begin at 3 p.m. Eastern ...
    (Date:5/4/2015)... Colo., May 4, 2015  Array BioPharma Inc. ... the third quarter of its fiscal year ending ... Executive Officer of Array, noted, "With the close of ... and encorafenib, two innovative oncology products in Phase ... product in 2016. These transformative transactions have accelerated ...
    (Date:5/4/2015)... HAVEN, Conn. , May 4, 2015 /PRNewswire/ ... chosen by the American Optometric Association (AOA) to ... delivery and outcomes for the millions of patients ... Measures and Outcomes Registry for Eyecare (MORE) ... will securely facilitate efficient secondary uses of essential ...
    Breaking Medicine Technology:Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10American Optometric Association, Prometheus Research to Create Transformative Health Outcomes Registry 2
    (Date:5/4/2015)... May 04, 2015 Dr. Richard Champagne, ... been chosen to receive the America’s Best Dentist Award, ... Champagne’s selection as a top dentist is a reflection ... continuing education and his compassion for his patients. , ... who exemplify excellence in their field. These nominees are ...
    (Date:5/4/2015)... World T.E.A.M. Sports’ best-attended Face of America ... decade arrived in this historic Civil War community April ... the Pentagon in Arlington, Virginia. The annual ride from ... participants work together to successfully complete the journey. , ... and sacrifices by military veterans in their defensive services. ...
    (Date:5/4/2015)... “ Food Cost Calculator ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... and efficiently calculate food costs. , The restaurant industry is ... industry has an estimated 1.8 trillion dollar impact on the ...
    (Date:5/4/2015)... 2015 Peacock Alley knows we ... said, “My mother was the most beautiful woman I ever ... lovely, feminine prints and textures to remind her ... than the Eloise Robe to get you there. The beautiful ... sleeve and tapered waist. It is available in small/medium or ...
    (Date:5/4/2015)... Angeles, California (PRWEB) May 04, 2015 ... a physician practice management firm in Los Angeles ... announced today the patent-pending status of The Sara Soulati ... by Soulati in 2010, is a lifestyle modification and ... in April 2015 to the U. S. Patents and ...
    Breaking Medicine News(10 mins):Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
    ... Feb. 11 Abbott ( NYSE: ABT ),today ... Food and Drug,Administration (FDA) for its new, compact ... expand the company,s hematology,platform by offering a high ... laboratories. , As small ...
    ... Inc., a privately held company located in the Midwest, ... eliminates all of the most common problems associated with ... therapy hasn,t always been therapeutic for many people. The ... never continue therapy beyond the first night ... because ...
    ... Tibotec Therapeutics, a division of Centocor Ortho ... a lower-dose (75 mg) formulation of PREZISTA (darunavir) ... the FDA approval of PREZISTA, co-administered with ritonavir ... treatment of HIV infection in pediatric patients six ...
    ... Men, Women Differ in Oral Health Care Habits , CHICAGO, ... what do people find most attractive in others? The smile. ... Crest(R) and Oral B(R) finds that the smile outranked eyes, ... men and women differ when it comes to taking care ...
    ... Ongoing Study Shows Seven of 14 Evaluable Patients ... Two Treatment Cycles----Bavituximab Has Now Produced Positive Early ... Therapy Cancer Trials--TUSTIN, Calif., Feb. 11 Peregrine ... reported that its lead product candidate bavituximab achieved ...
    ... Sanofi-aventis announced today that Jean-Pierre ... Chief Medical Officer (CMO). He was previously Senior ... Marc Cluzel, Senior Vice President, Research & Development, who ... Officer is a further demonstration internally and externally of ...
    Cached Medicine News:Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 3Health News:Husband From Small Town May Have Found Solution to Sleep Industry's 20-Year Compliance Problem 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 3Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 4Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 5Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 6Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 7Health News:Survey Finds Smile is 'Most Attractive' Physical Feature 2Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 2Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 3Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 4Health News:Jean-Pierre Lehner Appointed Chief Medical Officer 2
    ... Freedom® CMC ThumbFit™ reduces joint instability ... splint is remarkably comfortable and easy ... Kirby, OTR/L, CHT and Robert V. ... splint together in response to patients' ...
    ... of thumb motion can be difficult for ... persons with spinal cord injuries and for ... cerebral palsy or other motor or coordination ... thumb for control and coordination. Soft foam-lined ...
    ... the ThumSaver CMC Short lessens symptoms of arthritis, ... MP joints of the thumb. The ThumSaver CMC ... joint motion for function. Includes felt padding for ... for rest due to repetitive stress injuries. Right ...
    ... most common site for arthritis in the hand. ... restricting the wrist or other joints of the ... control or reduce subluxation of the CMC joint ... activities without pain. Also useful for persons experiencing ...
    Medicine Products: